INKT Stock Analysis: Buy, Sell, or Hold?
INKT - MiNK Therapeutics, Inc. Common Stock
$12.11
-0.22 (-1.78%)
▼
5d:
+2.54%
30d:
+11.41%
90d:
+41.47%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When INKT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: INKT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: INKT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: INKT is currently trading at $12.11, which is considered fair relative to its 30-day fair value range of $10.92 to $12.53.
Technical Outlook: Technically, INKT is showing sideways momentum. Immediate support is located at $10.13, while resistance sits at $13.40.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $39.00 (+222.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, INKT is showing sideways momentum. Immediate support is located at $10.13, while resistance sits at $13.40.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $39.00 (+222.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$10.92 -
$12.53
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 222.0% below Wall St target ($39.00)
Trading Range Analysis
30-Day Trading Range
$10.92 -
$12.53
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$10.13
Resistance Level
$13.40
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.24
Wall Street Target
$39.00
(+222.0%)
Share & Embed Analysis
Last updated: June 24, 2026 7:42 PM ET
Data refreshes hourly during market hours. Next update: 8:42 PM
Data refreshes hourly during market hours. Next update: 8:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INKT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Barbara Ryan
SELL
1300 shares
2026-03-10
Barbara Ryan
SELL
200 shares
2026-03-09
Barbara Ryan
SELL
100 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 57 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 58 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
